The ranibizumab biosimilar Ongavia exhibited significantly less improvement in visual acuity and retinal thickness compared ...
An add-on agent designed to boost drugs that treat age-related macular degeneration failed to show any benefit in two phase 3 ...
Following the negative results of the COAST Phase III trial announced on 24 March, Australia-based Opthea announced has updated on its clinical program, including the termination of COAST (Combination ...
The little hope left for Opthea shareholders has been crushed after the biotech said a second late-stage trial of its eye ...
Health on MSN6d
What To Know About Diabetic Macular Edema (DME)Medically reviewed by Danielle Weiss, MD Diabetic macular edema (DME) is a leading cause of vision loss in people with ...
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Paris and Tarrytown, NY, March 28, 2025. The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback